Ischemic StrokePhase 3NCT07730840
Zastaprazan for the prEvention of Upper GI Bleeding in Ischemic Stroke
A Phase 3 study testing Zastaprazan in people with Ischemic Stroke and Transient Ischemic Attack, run by Asan Medical Center at 15 sites in South Korea.
Trial summary
The goal of this clinical trial is to learn if zastaprazan can help prevent upper gastrointestinal bleeding in adults who have recently had a transient ischemic attack (TIA) or ischemic stroke and are taking antiplatelet or anticoagulant medications. Read more about this study
- Who is it for?
- Ages 19 years and older
- Conditions the study is for
- Ischemic Stroke, Transient Ischemic Attack
- What is being tested?
- Zastaprazan
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 984 participants
- Where
- 15 sitesSouth Korea
- Study dates
- 15 Oct 2026to 30 Sep 2029
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults aged 19 years or older
- Onset of transient ischemic attack (TIA) or ischemic stroke within 180 days prior to randomization
- Currently initiating or receiving, at the time of randomization, one of the following treatments, with an expected treatment duration of at least 3 weeks:
- Dual antiplatelet therapy (DAPT) - aspirin in combination with one of the following: clopidogrel, ticagrelor, prasugrel, or cilostazol B. Oral anticoagulant therapy - a NOAC (apixaban, rivaroxaban, dabigatran, or edoxaban) or warfarin
- Provision of written informed consent by the participant (or legally authorized representative)
Who cannot join
- Clinically significant peptic ulcer or gastrointestinal bleeding within 1 year prior to enrollment
- Moderate to severe hepatic impairment (e.g., diagnosis of cirrhosis or confirmed esophageal/gastric varices)
- Severe thrombocytopenia (platelet count <50,000/µL)
- End-stage renal disease requiring dialysis, or unstable renal function precluding safe anticoagulant dose adjustment (eGFR <15 mL/min/1.73m²)
- Known hypersensitivity to potassium-competitive acid blockers (P-CABs) or to the investigational product
- History of major gastrointestinal surgery resulting in malabsorption, bowel obstruction, or inability to take oral medication
Show all 18Show fewer
- History of osteoporotic fracture or fragility fracture
- Diagnosis of a condition requiring long-term, high-dose systemic corticosteroid therapy
- Diagnosis of a condition requiring long-term concomitant use of non-steroidal anti-inflammatory drugs (NSAIDs)
- Pregnant or breastfeeding women
- Life expectancy of less than 6 months due to pre-existing comorbid conditions
- Current participation in another interventional clinical trial that could affect the results of this study
- Any condition that, in the investigator's judgment, precludes participation
- Participant or partner of childbearing/reproductive potential who does not agree to use a medically acceptable method of contraception, or to abstain from sexual activity with risk of pregnancy, during the study period
- Currently receiving, or having received within 5 half-lives prior to randomization, a prohibited concomitant medication expected to interact with the investigational product (products containing atazanavir, nelfinavir, or rilpivirine)
- History of peptic ulcer complications, including bleeding, perforation, or stricture, regardless of timing
- Active bleeding at the time of enrollment, history of a coagulation disorder, or hemodynamic instability at the time of enrollment
- Known hereditary conditions such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
Trial locations and contacts
15 sites in 1 country. Contact the study team or a site near you to ask about taking part.
15 sites in 1 country
South Korea15 sites
Chungnam National University Hospital
Daejeon
Jong Wook Shin, MD, PhD, 82-1599-7123, dr.shin@hanmail.net
Chonnam National University Hospital
Gwangju
Kang-Ho Choi, MD, PhD, 82-1899-9000, ckhchoikang@hanmail.net
Ajou University Hospital
Gyeonggi-do
Hallym University Hospital
Gyeonggi-do
Mi Sun Oh, 82-1577-1801, iyyar0408@gmail.com
Seoul National University Bundang Hospital
Gyeonggi-do
Beom Joon Kim, MD, PhD, 82-1588-3369, kim.bj.stroke@gmail.com
Uijeongbu Eulji Medical Center, Eulji University
Gyeonggi-do
Dongwhane Lee, MD, PhD, 82-1899-0001, thepianist@naver.com
Catholic Kwandong University International St.Mary's Hospital
Incheon
Sang Joon An, MD, PhD, 82-1600-8291, neuroan@gmail.com
Jeju National University Hospital
Jeju City
Joong Goo Kim, MD, PhD, 82-64-717-1114, lilis1118@naver.com
Jeonbuk National University Hospital
Jeonju
Hyun Goo Kang, MD, PhD, 82-1577-7877, hgkang@jbnu.ac.kr
Asan Medical Center
Seoul, 05505
Bum Joon Kim, MD, PhD, +82-2-3010-3981, medicj80@hanmail.net
Ewha Womans University Seoul Hospital
Seoul
Tae-Jin Song, MD, PhD, 82-1522-7000, knstar@hanmail.net
Korea University Guro Hospital
Seoul
Chi Kyung Kim, MD, PhD, 82-1577-9966, ckkim7@gmail.com
Kyung Hee University Hospital
Seoul
Hogeol Woo, MD, PhD, 82-2-958-8114, nr85plasma@gmail.com
Samsung Medical Center
Seoul
Hyung Jun Kim, MD, PhD, 82-1599-3114, khhhj7@naver.com
Yonsei University Health System, Severance Hospital
Seoul
JoonNyung Heo, MD, PhD, 82-1599-1004, JNHEO@yuhs.ac
About this study
Official title: A Randomized, Double-Blind, Placebo-Controlled, Multi-center, Phase 3 Clinical Trial to Evaluate the Efficacy of Zastaprazan in PrEventing Upper Gastrointestinal Bleeding in Patients With Transient Ischemic Attack or Ischemic Stroke Receiving Antiplatelet or Anticoagulant Therapy: ZEUS Trial
The goal of this clinical trial is to learn if zastaprazan can help prevent upper gastrointestinal bleeding in adults who have recently had a transient ischemic attack (TIA) or ischemic stroke and are taking antiplatelet or anticoagulant medications. The main question it aims to answer is:
- Does zastaprazan reduce the risk of upper gastrointestinal bleeding compared to placebo in these patients?
Read more
Researchers will compare zastaprazan to a placebo (a look-alike tablet that contains no drug) to see if zastaprazan works to prevent upper gastrointestinal bleeding.
Participants will:
- Take zastaprazan (20 mg) or a placebo once daily for the duration of the study, in addition to their prescribed antiplatelet or anticoagulant medication
- Visit the study site regularly for safety monitoring, including vital signs, physical exams, and laboratory tests
- Be monitored for any signs of gastrointestinal bleeding or other adverse events for up to approximately 3 years (including screening, treatment, and follow-up periods)
- Conditions
- Ischemic Stroke, Transient Ischemic Attack
- Being tested
- Zastaprazan, Placebo
- Medical subject headings
- Ischemic Stroke, Ischemic Attack, Transient
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ZastaprazanDrug
Zastaprazan citrate 20 mg, a potassium-competitive acid blocker (P-CAB), administered orally once daily at a fixed dose, in addition to standard antiplatelet or anticoagulant therapy.
PlaceboDrug
Matching placebo for zastaprazan citrate 20 mg, administered orally once daily at a fixed dose, in addition to standard antiplatelet or anticoagulant therapy.
| Study group | Role | What they receive |
|---|---|---|
| Zastaprazan | Experimental | Participants will receive zastaprazan citrate 20 mg, administered orally once daily (QD) at a fixed dose, in addition to their prescribed antiplatelet therapy (dual antiplatelet therapy) or oral anticoagulant therapy (NOAC or warfarin). Receives: Drug: Zastaprazan |
| Placebo | Placebo comparator | Participants will receive a matching placebo for zastaprazan 20 mg, administered orally once daily (QD) at a fixed dose, in addition to their prescribed antiplatelet therapy (dual antiplatelet therapy) or oral anticoagulant therapy (NOAC or warfarin). Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time to First Composite Clinical Event of Upper Gastrointestinal Bleeding as Adjudicated by the Clinical Event Committee (CEC)
Time from randomization to the first occurrence of a composite clinical event of upper gastrointestinal (GI) bleeding, as adjudicated by the Clinical Event Committee (CEC). The composite event includes: (1) upper GI bleeding confirmed by endoscopy or imaging, with hematemesis and/or melena; (2) upper GI bleeding of unclear origin, judged by the investigator to originate from the upper GI tract; (3) occult GI bleeding, defined as a decrease in hemoglobin ≥2 g/dL or hematocrit ≥10%; (4) symptomatic uncomplicated gastroduodenal ulcer, confirmed by endoscopy or imaging with persistent pain (≥3 days) and no evidence of bleeding; (5) symptomatic gastroduodenal erosive lesions, with persistent pain (≥3 days) and ≥5 gastroduodenal erosions confirmed by endoscopy, excluding mucosal bleeding; (6) upper GI obstruction; and (7) upper GI perforation.
Measured: From randomization up to end of study (up to approximately 3 years, including a 24-month enrollment period and 12-month follow-up)
Secondary outcomes (15)
Time to First Composite Clinical Event of Upper Gastrointestinal Bleeding as Judged by the Investigator
Measured: From randomization up to end of study (up to approximately 3 years)
Time to First Upper Gastrointestinal Bleeding Event Confirmed by Endoscopy or Imaging, as Adjudicated by the Clinical Event Committee (CEC)
Measured: From randomization up to end of study (up to approximately 3 years)
Time to First Upper Gastrointestinal Bleeding Event of Unclear Origin, as Adjudicated by the Clinical Event Committee (CEC)
Measured: From randomization up to end of study (up to approximately 3 years)
Time to First Occult Gastrointestinal Bleeding Event, as Adjudicated by the Clinical Event Committee (CEC)
Measured: From randomization up to end of study (up to approximately 3 years)
Time to First Symptomatic Uncomplicated Gastroduodenal Ulcer Event, as Adjudicated by the Clinical Event Committee (CEC)
Measured: From randomization up to end of study (up to approximately 3 years)
Time to First Symptomatic Gastrointestinal Erosive Lesion Event, as Adjudicated by the Clinical Event Committee (CEC)
Measured: From randomization up to end of study (up to approximately 3 years)
Time to First Upper Gastrointestinal Obstruction Event, as Adjudicated by the Clinical Event Committee (CEC)
Measured: From randomization up to end of study (up to approximately 3 years)
Time to First Upper Gastrointestinal Perforation Event, as Adjudicated by the Clinical Event Committee (CEC)
Measured: From randomization up to end of study (up to approximately 3 years)
Time to First All Gastrointestinal Bleeding Event (Upper and Lower), Including International Society on Thrombosis and Haemostasis (ISTH) Major Bleeding or clinically relevant non-major bleeding (CRNMB)
Measured: From randomization up to end of study (up to approximately 3 years)
Time to First Lower Gastrointestinal Bleeding Event
Measured: From randomization up to end of study (up to approximately 3 years)
Time to First Non-Gastrointestinal ISTH Major Bleeding or CRNMB Event
Measured: From randomization up to end of study (up to approximately 3 years)
Time to First Clinically Significant Non-Bleeding Upper Gastrointestinal Event
Measured: From randomization up to end of study (up to approximately 3 years)
Time to First Hemoglobin-Related Event
Measured: From randomization up to end of study (up to approximately 3 years)
Time to First Cerebrovascular or Cardiovascular Event
Time from randomization to the first occurrence of a cerebrovascular or cardiovascular event, including ischemic stroke, transient ischemic attack, systemic embolism, myocardial infarction, or vascular death.
Measured: From randomization up to end of study (up to approximately 3 years)
All-Cause Mortality
Measured: From randomization up to end of study (up to approximately 3 years)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Jul 2026
- Study start15 Oct 2026 (estimated)
- Primary completion30 Sep 2029 (estimated)
- Study completion30 Sep 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Ischemic StrokeStudies of the same condition, open and under way.
- More trials run by Asan Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 984 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Asan Medical Center
- Sponsor type
- University, hospital or other
- Collaborators
- Jeil Pharmaceutical Co., Ltd.
- Responsible party
- Principal investigator, Bum Joon Kim, Asan Medical Center
- Investigators
- Bum Joon Kim, Ph.D., Principal investigator, Asan Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07730840
- Sponsor's protocol ID
- ZEUS
- Status last verified
- Oct 2026
- First submitted
- 23 Jul 2026
- Last updated
- 9 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-Blind, Placebo-Controlled, Multi-center, Phase 3 Clinical Trial to Evaluate the Efficacy of Zastaprazan in PrEventing Upper Gastrointestinal Bleeding in Patients With Transient Ischemic Attack or Ischemic Stroke Receiving Antiplatelet or Anticoagulant Therapy: ZEUS Trial
- ClinicalTrials.gov ID
- NCT07730840
- Acronym / sponsor ID
- ZEUS
- Conditions
- Ischemic Stroke, Transient Ischemic Attack
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 984 participants (estimated)
- Lead sponsor
- Asan Medical CenterUniversity, hospital or other
- Collaborators
- Jeil Pharmaceutical Co., Ltd.
- Study start
- 15 Oct 2026 (estimated)
- Primary completion
- 30 Sep 2029 (estimated)
- Study completion
- 30 Sep 2029 (estimated)
- First posted
- 28 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn if zastaprazan can help prevent upper gastrointestinal bleeding in adults who have recently had a transient ischemic attack (TIA) or ischemic stroke and are taking antiplatelet or anticoagulant medications. The main question it aims to answer is:
- Does zastaprazan reduce the risk of upper gastrointestinal bleeding compared to placebo in these patients?
Researchers will compare zastaprazan to a placebo (a look-alike tablet that contains no drug) to see if zastaprazan works to prevent upper gastrointestinal bleeding.
Participants will:
- Take zastaprazan (20 mg) or a placebo once daily for the duration of the study, in addition to their prescribed antiplatelet or anticoagulant medication
- Visit the study site regularly for safety monitoring, including vital signs, physical exams, and laboratory tests
- Be monitored for any signs of gastrointestinal bleeding or other adverse events for up to approximately 3 years (including screening, treatment, and follow-up periods)
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Zastaprazan | Experimental | Drug: ZastaprazanParticipants will receive zastaprazan citrate 20 mg, administered orally once daily (QD) at a fixed dose, in addition to their prescribed antiplatelet therapy (dual antiplatelet therapy) or oral anticoagulant therapy (NOAC or warfarin). |
| Placebo | Placebo comparator | Drug: PlaceboParticipants will receive a matching placebo for zastaprazan 20 mg, administered orally once daily (QD) at a fixed dose, in addition to their prescribed antiplatelet therapy (dual antiplatelet therapy) or oral anticoagulant therapy (NOAC or warfarin). |
Who may qualify
- Ages
- 19 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Adults aged 19 years or older
- Onset of transient ischemic attack (TIA) or ischemic stroke within 180 days prior to randomization
- Currently initiating or receiving, at the time of randomization, one of the following treatments, with an expected treatment duration of at least 3 weeks:
- Provision of written informed consent by the participant (or legally authorized representative)
Key exclusion criteria (18 listed)
- Clinically significant peptic ulcer or gastrointestinal bleeding within 1 year prior to enrollment
- Moderate to severe hepatic impairment (e.g., diagnosis of cirrhosis or confirmed esophageal/gastric varices)
- Severe thrombocytopenia (platelet count <50,000/µL)
- End-stage renal disease requiring dialysis, or unstable renal function precluding safe anticoagulant dose adjustment (eGFR <15 mL/min/1.73m²)
- Known hypersensitivity to potassium-competitive acid blockers (P-CABs) or to the investigational product
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ZastaprazanZastaprazan citrate 20 mg, a potassium-competitive acid blocker (P-CAB), administered orally once daily at a fixed dose, in addition to standard antiplatelet or anticoagulant therapy. | Drug | Zastaprazan |
| PlaceboMatching placebo for zastaprazan citrate 20 mg, administered orally once daily at a fixed dose, in addition to standard antiplatelet or anticoagulant therapy. | Drug | Placebo |
Primary outcome
Time to First Composite Clinical Event of Upper Gastrointestinal Bleeding as Adjudicated by the Clinical Event Committee (CEC)
Time frame: From randomization up to end of study (up to approximately 3 years, including a 24-month enrollment period and 12-month follow-up)
Time from randomization to the first occurrence of a composite clinical event of upper gastrointestinal (GI) bleeding, as adjudicated by the Clinical Event Committee (CEC). The composite event includes: (1) upper GI bleeding confirmed by endoscopy or imaging, with hematemesis and/or melena; (2) upper GI bleeding of unclear origin, judged by the investigator to originate from the upper GI tract; (3) occult GI bleeding, defined as a decrease in hemoglobin ≥2 g/dL or hematocrit ≥10%; (4) symptomatic uncomplicated gastroduodenal ulcer, confirmed by endoscopy or imaging with persistent pain (≥3 days) and no evidence of bleeding; (5) symptomatic gastroduodenal erosive lesions, with persistent pain (≥3 days) and ≥5 gastroduodenal erosions confirmed by endoscopy, excluding mucosal bleeding; (6) upper GI obstruction; and (7) upper GI perforation.
15 secondary outcomes
Time to First Composite Clinical Event of Upper Gastrointestinal Bleeding as Judged by the Investigator
Time frame: From randomization up to end of study (up to approximately 3 years)
Time to First Upper Gastrointestinal Bleeding Event Confirmed by Endoscopy or Imaging, as Adjudicated by the Clinical Event Committee (CEC)
Time frame: From randomization up to end of study (up to approximately 3 years)
Time to First Upper Gastrointestinal Bleeding Event of Unclear Origin, as Adjudicated by the Clinical Event Committee (CEC)
Time frame: From randomization up to end of study (up to approximately 3 years)
Time to First Occult Gastrointestinal Bleeding Event, as Adjudicated by the Clinical Event Committee (CEC)
Time frame: From randomization up to end of study (up to approximately 3 years)
Time to First Symptomatic Uncomplicated Gastroduodenal Ulcer Event, as Adjudicated by the Clinical Event Committee (CEC)
Time frame: From randomization up to end of study (up to approximately 3 years)
Time to First Symptomatic Gastrointestinal Erosive Lesion Event, as Adjudicated by the Clinical Event Committee (CEC)
Time frame: From randomization up to end of study (up to approximately 3 years)
Time to First Upper Gastrointestinal Obstruction Event, as Adjudicated by the Clinical Event Committee (CEC)
Time frame: From randomization up to end of study (up to approximately 3 years)
Time to First Upper Gastrointestinal Perforation Event, as Adjudicated by the Clinical Event Committee (CEC)
Time frame: From randomization up to end of study (up to approximately 3 years)
Time to First All Gastrointestinal Bleeding Event (Upper and Lower), Including International Society on Thrombosis and Haemostasis (ISTH) Major Bleeding or clinically relevant non-major bleeding (CRNMB)
Time frame: From randomization up to end of study (up to approximately 3 years)
Time to First Lower Gastrointestinal Bleeding Event
Time frame: From randomization up to end of study (up to approximately 3 years)
Time to First Non-Gastrointestinal ISTH Major Bleeding or CRNMB Event
Time frame: From randomization up to end of study (up to approximately 3 years)
Time to First Clinically Significant Non-Bleeding Upper Gastrointestinal Event
Time frame: From randomization up to end of study (up to approximately 3 years)
Time to First Hemoglobin-Related Event
Time frame: From randomization up to end of study (up to approximately 3 years)
Time to First Cerebrovascular or Cardiovascular Event
Time frame: From randomization up to end of study (up to approximately 3 years)
All-Cause Mortality
Time frame: From randomization up to end of study (up to approximately 3 years)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Ischemic Stroke
Not yet recruiting
Temporal Interference Stimulation for Upper-Limb Motor Recovery in Early Subacute Stroke
Acute Ischemic Stroke
RecruitingObservational study
ELATE Study: Evaluating Large-vessel Acute Thrombectomy in Extended Time Window
Acute Ichemic Stroke
Not yet recruiting
Selective Intra-Arterial Hypothermia After Endovascular Treatment for Acute Basilar Artery Occlusion
Acute Ischemic Stroke, Basilar Artery Occlusion
Active, not recruiting
Improving Visual Field Deficits With Noninvasive Brain Stimulation
Visual Field Defect, Peripheral, Stroke
Recruiting
Biomarkers of Paired VNS
Stroke, Ischemic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Bum Joon Kim, Ph.D. principal investigator
Asan Medical Center
15 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Zastaprazan in people with Ischemic Stroke and Transient Ischemic Attack, run by Asan Medical Center at 15 sites in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 9 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 15 sites in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Bum Joon Kim, MD, Ph.D. (+82-2- 3010-3981, bj.kim@amc.seoul.kr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time to First Composite Clinical Event of Upper Gastrointestinal Bleeding as Adjudicated by the Clinical Event Committee (CEC) (time frame: From randomization up to end of study (up to approximately 3 years, including a 24-month enrollment period and 12-month follow-up)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Oct 2026.